Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial. (2017)

First Author: Cunningham D
Attributed to:  CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(17)30043-8

PubMed Identifier: 28163000

Publication URI: http://europepmc.org/abstract/MED/28163000

Type: Journal Article/Review

Volume: 18

Parent Publication: The Lancet. Oncology

Issue: 3

ISSN: 1470-2045